Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the formation of a newly organized, artificial intelligence (“AI”) business unit, led by Chief Technology & AI Officer Christopher Thurston, to integrate the Company’s existing and planned AI applications into the Co-Dx™ Primer Ai™ platform.